查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1994186

球囊瓣環成形裝置市場：依產品類型、方法、患者年齡、適應症及最終用戶分類－2026-2032年全球市場預測

Balloon Valvuloplasty Device Market by Product Type, Approach, Patient Age, Indication, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，球囊瓣環成形裝置市場價值將達到 24.7 億美元，到 2026 年將成長至 26.4 億美元，到 2032 年將達到 42.5 億美元，複合年成長率為 8.08%。

主要市場統計數據
基準年 2025 24.7億美元
預計年份：2026年 26.4億美元
預測年份 2032 42.5億美元
複合年成長率 (%) 8.08%

為決策者提供關於球囊瓣環成形裝置的權威指導，闡明臨床促進因素、裝置設計要求和策略重點。

本執行摘要重點概述了球囊瓣環成形裝置市場，闡述了臨床促進因素、技術趨勢和相關人員需求，旨在指南採購和臨床策略。它整合了臨床實踐模式、不斷發展的裝置設計、部署方法和醫療機構的採納趨勢，為經營團隊決策奠定了切實可行的基礎。

診斷影像技術的進步、流程的去中心化以及不斷變化的監管預期正在如何重塑臨床應用和設備開發。

由於臨床、技術和系統性因素的共同作用，球囊瓣環成形領域正經歷變革性的轉變。影像學、導管介入技術和輔助手術工具的進步，拓展了瓣環成形的適用解剖結構和病患群體，同時也提高了人們對手術精準性和持久性的期望。因此，器械研發人員正致力於提升輸送性能、最佳化可控擴張機制，並在手術過程中整合影像技術，以減少併發症並縮短訓練時間。

2025 年美國關稅對設備供應鏈、採購趨勢和策略性成本降低方法的多方面商業性影響。

美國於2025年宣布的關稅政策，將球囊瓣環成形器材製造商、經銷商和醫療服務提供者面臨的商業複雜性提升到了一個新的高度。關稅調整影響了原料成本、零件採購政策以及跨境供應鏈的最佳化，迫使許多企業重新評估供應商合約和製造地。為此，一些製造商正在加快供應商多元化和近岸生產佈局的步伐，以維持利潤率並確保供應的連續性。

一個整合了適應症、設備類型、臨床環境、入路方式和年齡層的多層分割分類系統，為產品和臨床策略指南。

細分分析揭示了不同適應症、產品類型、終端使用者、手術方法和患者年齡層在臨床需求和商業性機會方面的多樣性。基於適應症，本研究對主動脈瓣環成形、二尖瓣瓣環成形、肺動脈瓣環成形和瓣環成形市場進行了調查，並根據解剖結構和臨床管理要求，將每個瓣膜類別進一步細分為成人和兒童組。這種多層次的適應症框架表明，與肺動脈瓣和三尖瓣手術相比，主動脈瓣和二尖瓣手術需要不同的器械特性和操作者技能。此外，該框架還顯示，兒童醫學在患者生長發育和器械尺寸選擇方面存在獨特的限制。

美洲、歐洲、中東和非洲以及亞太地區的監管多樣性、支付方結構和不斷發展的服務能力如何決定部署路徑和商業化策略。

區域趨勢正在塑造美洲、歐洲、中東和非洲（EMEA）以及亞太地區不同的應用模式、報銷框架和供應鏈結構。在美洲，醫療保健整合、多元化的支付方結構以及成熟的心臟導管介入生態系統正在推動對兼具臨床療效和顯著經濟價值的器材的需求。這些市場的法規環境和手術報銷途徑促使製造商優先考慮臨床夥伴關係和結果資料收集，以評估能夠證明療效改善的證據。

深入剖析競爭策略，揭示產品改進、臨床夥伴關係和結果證據如何成為決定性的商業性槓桿。

球囊瓣環成形器材領域的競爭主要集中在產品差異化、臨床證據的累積以及能夠降低醫療機構實施風險的夥伴關係模式。主要企業正致力於產品迭代改進，以提高可追溯性、球囊順應性精度以及與術中影像的兼容性。這些技術改進旨在降低併發症率，並將瓣環成形修復的範圍擴大到解剖結構複雜的病變以及更年輕或病情更複雜的患者群體。

製造商和醫療保健提供者的具體策略重點，旨在透過卓越的產品、證據產生和強大的供應鏈來加速產品推廣應用。

產業領導企業應優先考慮一系列切實可行的舉措，使產品開發、臨床合作和商業性執行與當前部署挑戰保持一致。首先，應投資於能夠顯著降低手術操作差異並使其可在任何醫療環境中部署的設備特性。這包括改進交付方式、可預測的可擴展性以及與影像設備的兼容性，這將增強臨床醫生的信心並擴大適用機構的範圍。同時，必須設計培訓和指導計劃，以縮短學習曲線並將最佳手術操作實踐融入本地通訊協定，從而支援更安全、更有效率的部署。

嚴謹的多面向研究途徑，結合與臨床醫師的對話、監管分析和臨床文獻的整合，得出切實可行的策略結論。

本執行摘要的調查方法採用多方面策略，結合與關鍵相關人員的對話、監管文件分析以及同行評審的臨床文獻，建構平衡的證據基礎。主要資訊來源包括介入性心臟病專家、器材研發工程師和醫院採購經理的結構化訪談。這些訪談旨在了解醫療環境中真實的決策標準、手術偏好和挑戰。為補充主要訪談內容，我們也查閱了監管申報文件和指導文件，以了解瓣環成形器械的核准流程和上市後要求。

一個重要的結論觀點強調，瓣環成形手術的長期成功取決於臨床創新、高度適應性的商業化和供應彈性的結合。

總之，球囊瓣環成形裝置的發展受到三大因素的影響：臨床創新、不斷演變的醫療服務模式、不斷變化的政策壓力。提升手術精準度和與最新影像技術相容性的裝置改進，將在擴大其在成人和兒童患者群體中的合理應用方面發揮核心作用。同時，醫療服務的去中心化也為那些不僅能在三級醫療機構可靠運行，也能在門診和專科機構可靠運行的裝置提供了新的機遇，前提是培訓和指導能夠降低治療結果的差異性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 球囊瓣環成形裝置市場：依產品類型分類

  • 傳統球囊
  • 切割球囊

第9章：依方法分類的球囊瓣環成形裝置市場

  • 股動脈通路
  • 經頸靜脈
  • 心房隔膜通路

第10章：依病患年齡分類的球囊瓣環成形裝置市場

  • 成人版
  • 兒童

第11章 球囊瓣環成形裝置市場：依適應症分類

  • 主動脈瓣環成形
    • 成人版
    • 兒童
  • 二尖瓣瓣環成形手術
    • 成人版
    • 兒童
  • 肺動脈瓣環成形手術
    • 成人版
    • 兒童
  • 瓣環成形
    • 成人版
    • 兒童

第12章 球囊瓣環成形裝置市場：依最終用戶分類

  • 門診手術中心
  • 心臟科中心
  • 醫院

第13章 球囊瓣環成形裝置市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 球囊瓣環成形裝置市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 球囊瓣環成形裝置市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國球囊瓣環成形裝置市場

第17章：中國球囊瓣環成形裝置市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • B. Braun Melsungen AG
  • Balton Sp. z oo
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Cardiovascular Systems, Inc.
  • Colibri Heart Valve LLC
  • Cook Medical LLC
  • Edwards Lifesciences Corporation
  • Eurocor GmbH
  • Getinge AB
  • Hexacath SAS
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • MicroPort Scientific Corporation
  • NuMED, Inc.
  • OOO Vonadi
  • Osypka Medical GmbH
  • Scitech Medical Products Ltd.
  • Shenzhen Lifotronic Technology Co., Ltd.
  • Somo International Co., Ltd.
  • Terumo Corporation
  • Toray International, Inc.
  • TT Medical Co., Ltd.
Product Code: MRR-1A1A064C0466

The Balloon Valvuloplasty Device Market was valued at USD 2.47 billion in 2025 and is projected to grow to USD 2.64 billion in 2026, with a CAGR of 8.08%, reaching USD 4.25 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.47 billion
Estimated Year [2026] USD 2.64 billion
Forecast Year [2032] USD 4.25 billion
CAGR (%) 8.08%

An authoritative orientation to balloon valvuloplasty devices that clarifies clinical drivers, device design imperatives, and strategic priorities for decision-makers

This executive summary offers a focused orientation to the balloon valvuloplasty device environment, clarifying clinical drivers, technology vectors, and stakeholder imperatives that inform procurement and clinical strategy. It synthesizes clinical practice patterns, device design evolution, delivery approaches, and provider adoption dynamics to create a practical foundation for executive decision-making.

Clinicians and commercial leaders face a landscape where procedural technique, patient selection, and device attributes converge to determine outcomes and resource allocation. The procedural spectrum spans interventions for aortic, mitral, pulmonary, and tricuspid valve stenoses across adult and pediatric populations, and each indication carries distinct anatomical, hemodynamic, and regulatory considerations. Consequently, manufacturers and health systems must align product design and training programs with the nuanced needs of diverse clinical teams and age cohorts.

This summary prioritizes clarity and actionable insight. It outlines the transformative shifts reshaping procedural choices and procurement priorities, evaluates the implications of recent policy actions on the cost and distribution chain, and highlights segmentation and regional patterns that matter for commercialization. The goal is to provide an immediately usable synthesis that executives and clinical leaders can apply to product strategy, market access planning, and clinical education initiatives.

How advances in imaging, procedural decentralization, and evolving regulatory expectations are converging to reshape clinical adoption and device development

The balloon valvuloplasty landscape is undergoing transformative shifts driven by converging clinical, technological, and system-level forces. Advances in imaging, catheter technologies, and adjunctive procedural tools are expanding the range of anatomies and patient profiles amenable to valvuloplasty while simultaneously raising expectations for procedural precision and durability. As a result, device developers are focusing on deliverability, controlled expansion mechanics, and integration with intraprocedural imaging to reduce complications and shorten learning curves.

At the same time, care delivery is decentralizing in many markets, with ambulatory surgical centers and specialty cardiac centers increasingly performing elective structural interventions. This shift places a premium on devices that facilitate predictable, efficient procedures with minimal cross-disciplinary resource requirements. Translational research coupling device engineering with clinical workflows has accelerated incremental innovations, including refinements in balloon compliance profiles and cutting balloon technologies designed to address calcified or complex lesions.

Regulatory pathways and reimbursement frameworks are adapting in parallel, creating both opportunities and friction for device adoption. The increased emphasis on real-world evidence and value demonstration requires stakeholders to plan for post-market data collection and outcome reporting. Moreover, collaboration between manufacturers, clinical investigators, and health systems is becoming more strategic, as partnerships that de-risk adoption through training, bundled care pathways, and shared data platforms are favored. These forces collectively recalibrate how stakeholders prioritize R&D investment, clinical education, and market entry sequencing.

The multifaceted commercial implications of 2025 United States tariffs on device supply chains, procurement dynamics, and strategic cost mitigation approaches

United States tariffs announced for 2025 have introduced a new layer of commercial complexity for manufacturers, distributors, and providers involved in balloon valvuloplasty devices. Tariff adjustments influenced raw material costs, component sourcing decisions, and cross-border supply chain optimization, prompting many organizations to reassess supplier contracts and manufacturing footprints. In response, several manufacturers have accelerated supplier diversification and nearshoring initiatives to preserve margin and ensure continuity of supply.

The cumulative effect of tariff-driven input cost shifts extends beyond manufacturing. Procurement teams within hospitals and specialty centers have encountered increased variability in device pricing and lead times, which has, in turn, affected contract negotiations and inventory management strategies. Clinical purchasers are increasingly demanding transparent total cost of ownership analyses that account for acquisition price, logistical risk, and the potential for price volatility tied to policy shifts. As a result, procurement strategy now often incorporates scenario planning and contingency inventory buffers to mitigate disruption.

From a strategic perspective, tariffs have encouraged a stronger focus on value-creation measures that can offset incremental cost pressure. Manufacturers are emphasizing clinical differentiators that translate into reduced length of stay, lower complication rates, or fewer reinterventions, thereby strengthening total cost narratives for payers and providers. Additionally, some players have pursued modularization of components and alternative materials that maintain clinical performance while reducing exposure to tariff-sensitive inputs. These adaptations illustrate how trade policy can catalyze both short-term operational changes and longer-term strategic reorientation across the device ecosystem.

A layered segmentation taxonomy uniting indications, device types, care settings, access approaches, and age cohorts to guide product and clinical strategies

Segmentation insights reveal the heterogeneity of clinical need and commercial opportunity across indications, product types, end users, approaches, and patient age cohorts. Based on Indication, the market is studied across Aortic Valvuloplasty, Mitral Valvuloplasty, Pulmonary Valvuloplasty, and Tricuspid Valvuloplasty, with each valve category further stratified into Adult and Pediatric cohorts to reflect divergent anatomical and clinical management requirements. This layered indication framework clarifies that aortic and mitral interventions often demand different device profiles and operator skill sets compared with pulmonary and tricuspid procedures, and that pediatric practice imposes specific constraints related to patient growth and device sizing.

Based on Product Type, the market is studied across Conventional Balloon and Cutting Balloon, which underlines a fundamental design dichotomy: conventional balloons prioritize uniform dilation and simplicity, while cutting balloon technologies aim to address resistant or heavily fibrosed lesions with controlled incisions. Device selection between these options is informed by lesion pathology, operator experience, and institutional protocols. Based on End User, the market is studied across Ambulatory Surgical Center, Cardiac Specialty Center, and Hospital, reflecting how procedure setting influences purchasing criteria, training needs, and reimbursement dynamics. Ambulatory sites typically prioritize throughput and minimized resource intensity, specialty centers emphasize procedural specialization and outcome optimization, and hospitals balance complexity management with broader system responsibilities.

Based on Approach, the market is studied across Transfemoral, Transjugular, and Transseptal access routes, each associated with distinct anatomical access considerations, catheter design requirements, and operator skill profiles. Transfemoral approaches often favor streamlined delivery systems and compatibility with existing sheath infrastructure, whereas transjugular and transseptal techniques may necessitate alternative catheter geometries and navigation tooling. Finally, Based on Patient Age, the market is studied across Adult and Pediatric cohorts, highlighting how growth considerations, device scalability, and long-term follow-up strategies are particularly salient for younger patients. Taken together, these segmentation layers provide a practical taxonomy for aligning product design, clinical training, and market entry planning with real-world procedural heterogeneity.

How regional regulatory diversity, payer structures, and evolving service capacity across the Americas, EMEA, and Asia-Pacific determine adoption pathways and commercialization tactics

Regional dynamics shape adoption patterns, reimbursement frameworks, and supply chain configurations in distinct ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, provider consolidation, diverse payer arrangements, and a mature interventional cardiology ecosystem drive demand for devices that balance clinical performance with demonstrable economic value. The regulatory environment and procedural reimbursement pathways in these markets reward evidence of improved outcomes, prompting manufacturers to prioritize clinical partnerships and outcomes data collection.

Within Europe, Middle East & Africa, stakeholders navigate a mosaic of national regulatory regimes, reimbursement models, and care delivery capabilities. This diversity favors flexible commercialization strategies that combine local clinical champions with regionally tailored training programs and distribution models. Outcomes data and health technology assessment practices play a central role in adoption, making robust clinical evidence and pharmacoeconomic narratives critical for market entry and scale.

Asia-Pacific represents a rapidly evolving landscape with heterogeneous healthcare infrastructure and growing investment in interventional cardiology capacity. In several markets, expanding access to specialty centers and increasing procedural expertise are supporting broader adoption of valvuloplasty procedures across adult and pediatric populations. Regional manufacturers and global suppliers alike are adapting to variable procurement policies and cost sensitivities by offering differentiated product portfolios and localized service models that accommodate diverse hospital capabilities. Across all regions, supply chain resilience and regulatory agility remain central determinants of commercial success.

Insights into competitive strategies revealing how product refinement, clinical partnerships, and outcome evidence are becoming decisive commercial levers

Competitive behavior in the balloon valvuloplasty device space centers on product differentiation, clinical evidence generation, and partnership models that de-risk adoption for providers. Leading companies are investing in iterative product enhancements that improve trackability, balloon compliance fidelity, and compatibility with intraprocedural imaging modalities. These technical improvements aim to reduce complication rates and to expand candidacy for valvuloplasty across anatomically challenging lesions and younger or more complex patient cohorts.

Strategic alliances and clinical collaborations are common, as device manufacturers recognize that demonstrating downstream value often requires integrated training programs, registry participation, and collaborative research with high-volume centers. Commercial teams increasingly offer bundled solutions that combine devices with procedural training, support for registry enrollment, and outcome-monitoring services. Distribution strategy is another focal point, with some organizations prioritizing direct relationships with large health systems while others leverage specialty distributors to reach ambulatory and regional centers.

Companies are also optimizing regulatory and post-market strategies by investing in real-world evidence platforms that capture outcomes across care settings. These data assets support reimbursement discussions and bolster clinical credibility. Finally, a number of players are exploring modular product architectures and component standardization to reduce manufacturing complexity, improve supply chain resilience, and enable faster iterations based on clinician feedback. Collectively, these approaches reflect a competitive environment where clinical efficacy, operational efficiency, and strategic partnerships determine who secures enduring provider preference.

Actionable strategic priorities for manufacturers and providers to accelerate adoption through product excellence, evidence generation, and resilient supply chains

Industry leaders should prioritize a set of actionable initiatives that align product development, clinical engagement, and commercial execution with contemporary adoption challenges. First, invest in device attributes that materially reduce procedural variability and enable adoption across care settings: improved deliverability, predictable expansion characteristics, and compatibility with imaging modalities will accelerate clinician confidence and broaden site suitability. Concurrently, design training and proctoring programs that shorten the learning curve and embed procedural best practices into local protocols to support safer, more efficient adoption.

Second, build robust real-world evidence initiatives that capture outcomes across hospitals, cardiac specialty centers, and ambulatory surgical centers. Evidence that links device use to reduced complications, fewer reinterventions, or shortened recovery pathways strengthens value conversations with payers and procurement stakeholders and can offset headwinds introduced by input cost volatility. Third, reassess supply chain strategies to mitigate tariff and trade policy exposure; diversifying component suppliers, nearshoring critical manufacturing steps, and creating contingency inventory frameworks will reduce operational risk.

Fourth, tailor commercial models to regional and end-user nuances. Offer flexible pricing and service bundles that reflect the differing priorities of ambulatory centers versus tertiary hospitals, and deploy dedicated clinical education resources to support specialty centers that serve complex cases. Finally, pursue partnerships with imaging and navigation technology providers where integration can produce compelling clinical advantages. By coordinating technical innovation with evidence generation and supply resilience, leaders can enhance adoption and protect margins under dynamic policy and reimbursement conditions.

A rigorous multi-source research approach combining clinician engagement, regulatory analysis, and clinical literature synthesis to inform practical strategic conclusions

The research methodology underpinning this executive summary integrates a multi-source approach combining primary stakeholder engagement, regulatory document analysis, and synthesis of peer-reviewed clinical literature to form a balanced evidence base. Primary inputs include structured interviews with interventional cardiologists, device development engineers, and hospital procurement leads; these conversations were designed to capture real-world decision criteria, procedural preferences, and pain points across care settings. Supplementing primary interviews, regulatory filings and guidance documents were reviewed to map approval pathways and post-market requirements relevant to valvuloplasty devices.

Clinical literature and guideline statements were surveyed to contextualize procedural indications, outcomes expectations, and evolving best practices. This literature synthesis emphasized comparative device characteristics and reported procedural outcomes while avoiding extrapolation beyond published evidence. The analytical framework combined thematic coding of qualitative interview data with cross-validation against the clinical and regulatory record to identify consistent trends and areas of divergence.

Limitations of the methodology are acknowledged: primary interviews reflect the perspectives of selected high-volume clinicians and commercial stakeholders and may not capture all regional practice variations. Moreover, regulatory interpretation was based on publicly available documents at the time of analysis, and stakeholders should anticipate iterative changes as agencies respond to new evidence. Despite these caveats, the approach ensures that conclusions are grounded in clinician experience, regulatory context, and peer-reviewed clinical data, providing a robust foundation for strategic decision-making.

Essential closing perspectives emphasizing how clinical innovation, adaptable commercialization, and supply resilience collectively determine long-term success in valvuloplasty

In conclusion, balloon valvuloplasty devices sit at the intersection of clinical innovation, shifting care delivery models, and evolving policy pressures. Device improvements that enhance procedural precision and compatibility with modern imaging techniques will be central to expanding appropriate use across adult and pediatric cohorts. Meanwhile, decentralization of care creates opportunities for devices designed to perform reliably in ambulatory and specialty settings as well as tertiary hospitals, provided that training and proctoring reduce variability in outcomes.

Policy developments, such as tariff changes and adjustments in reimbursement practices, underscore the need for supply chain agility and compelling value narratives. Manufacturers that pair meaningful clinical differentiators with robust evidence-generation programs and flexible commercialization models will be best positioned to navigate these challenges. Providers and payers will increasingly demand transparent total cost of care analyses that reflect not only device price but also downstream impacts on length of stay, complication rates, and reintervention frequency.

Overall, stakeholders who coordinate device innovation, clinical partnership, and operational resilience can accelerate safe adoption and create durable advantages. The strategic imperative is clear: integrate clinical excellence with pragmatic commercial planning to realize the therapeutic potential of valvuloplasty while managing policy and operational headwinds.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Balloon Valvuloplasty Device Market, by Product Type

  • 8.1. Conventional Balloon
  • 8.2. Cutting Balloon

9. Balloon Valvuloplasty Device Market, by Approach

  • 9.1. Transfemoral
  • 9.2. Transjugular
  • 9.3. Transseptal

10. Balloon Valvuloplasty Device Market, by Patient Age

  • 10.1. Adult
  • 10.2. Pediatric

11. Balloon Valvuloplasty Device Market, by Indication

  • 11.1. Aortic Valvuloplasty
    • 11.1.1. Adult
    • 11.1.2. Pediatric
  • 11.2. Mitral Valvuloplasty
    • 11.2.1. Adult
    • 11.2.2. Pediatric
  • 11.3. Pulmonary Valvuloplasty
    • 11.3.1. Adult
    • 11.3.2. Pediatric
  • 11.4. Tricuspid Valvuloplasty
    • 11.4.1. Adult
    • 11.4.2. Pediatric

12. Balloon Valvuloplasty Device Market, by End User

  • 12.1. Ambulatory Surgical Center
  • 12.2. Cardiac Specialty Center
  • 12.3. Hospital

13. Balloon Valvuloplasty Device Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Balloon Valvuloplasty Device Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Balloon Valvuloplasty Device Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Balloon Valvuloplasty Device Market

17. China Balloon Valvuloplasty Device Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. B. Braun Melsungen AG
  • 18.7. Balton Sp. z o.o.
  • 18.8. Becton, Dickinson and Company
  • 18.9. Boston Scientific Corporation
  • 18.10. Cardiovascular Systems, Inc.
  • 18.11. Colibri Heart Valve LLC
  • 18.12. Cook Medical LLC
  • 18.13. Edwards Lifesciences Corporation
  • 18.14. Eurocor GmbH
  • 18.15. Getinge AB
  • 18.16. Hexacath SAS
  • 18.17. Lepu Medical Technology (Beijing) Co., Ltd.
  • 18.18. Medtronic plc
  • 18.19. Merit Medical Systems, Inc.
  • 18.20. MicroPort Scientific Corporation
  • 18.21. NuMED, Inc.
  • 18.22. OOO Vonadi
  • 18.23. Osypka Medical GmbH
  • 18.24. Scitech Medical Products Ltd.
  • 18.25. Shenzhen Lifotronic Technology Co., Ltd.
  • 18.26. Somo International Co., Ltd.
  • 18.27. Terumo Corporation
  • 18.28. Toray International, Inc.
  • 18.29. TT Medical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY APPROACH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PATIENT AGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BALLOON VALVULOPLASTY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY CONVENTIONAL BALLOON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY CONVENTIONAL BALLOON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY CONVENTIONAL BALLOON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY CUTTING BALLOON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY CUTTING BALLOON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY CUTTING BALLOON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY TRANSFEMORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY TRANSFEMORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY TRANSFEMORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY TRANSJUGULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY TRANSJUGULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY TRANSJUGULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY TRANSSEPTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY TRANSSEPTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY TRANSSEPTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY AORTIC VALVULOPLASTY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY AORTIC VALVULOPLASTY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY AORTIC VALVULOPLASTY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY AORTIC VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY MITRAL VALVULOPLASTY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY MITRAL VALVULOPLASTY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY MITRAL VALVULOPLASTY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY MITRAL VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PULMONARY VALVULOPLASTY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PULMONARY VALVULOPLASTY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PULMONARY VALVULOPLASTY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PULMONARY VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY TRICUSPID VALVULOPLASTY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY TRICUSPID VALVULOPLASTY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY TRICUSPID VALVULOPLASTY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY TRICUSPID VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY CARDIAC SPECIALTY CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY CARDIAC SPECIALTY CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY CARDIAC SPECIALTY CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY AORTIC VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY MITRAL VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PULMONARY VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY TRICUSPID VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY AORTIC VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY MITRAL VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PULMONARY VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY TRICUSPID VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY AORTIC VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY MITRAL VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PULMONARY VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY TRICUSPID VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY AORTIC VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY MITRAL VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PULMONARY VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY TRICUSPID VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY AORTIC VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY MITRAL VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PULMONARY VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY TRICUSPID VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY AORTIC VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY MITRAL VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PULMONARY VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY TRICUSPID VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY AORTIC VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY MITRAL VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PULMONARY VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY TRICUSPID VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY AORTIC VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY MITRAL VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PULMONARY VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY TRICUSPID VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY AORTIC VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY MITRAL VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PULMONARY VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY TRICUSPID VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. GCC BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GCC BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. GCC BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 172. GCC BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 173. GCC BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 174. GCC BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY AORTIC VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 175. GCC BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY MITRAL VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 176. GCC BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PULMONARY VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 177. GCC BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY TRICUSPID VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 178. GCC BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY AORTIC VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY MITRAL VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PULMONARY VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY TRICUSPID VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY AORTIC VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY MITRAL VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PULMONARY VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY TRICUSPID VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. G7 BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. G7 BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. G7 BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 202. G7 BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 203. G7 BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 204. G7 BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY AORTIC VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 205. G7 BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY MITRAL VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 206. G7 BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PULMONARY VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 207. G7 BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY TRICUSPID VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 208. G7 BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. NATO BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. NATO BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 212. NATO BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 213. NATO BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 214. NATO BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY AORTIC VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 215. NATO BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY MITRAL VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 216. NATO BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PULMONARY VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 217. NATO BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY TRICUSPID VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 218. NATO BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES BALLOON VALVULOPLASTY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY AORTIC VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY MITRAL VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PULMONARY VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY TRICUSPID VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY AORTIC VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY MITRAL VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY PULMONARY VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY TRICUSPID VALVULOPLASTY, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA BALLOON VALVULOPLASTY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)